Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Dalteparin may be effective in inhibiting the growth of blood vessels in tumors,
decreasing the risk of metastatic cancer, preventing the formation of blood clots, and
improving quality of life in treating patients with advanced cancer that has not responded to
previous treatment. It is not yet known if standard therapy is more effective with or without
dalteparin in treating advanced breast, lung, colorectal, and prostate cancer.
PURPOSE: Randomized double blinded phase III trial to compare the effectiveness of standard
therapy with or without dalteparin in treating patients who have advanced breast, lung,
colorectal, or prostate cancer that has not responded to previous chemotherapy or hormone
therapy.